Case Comprehensive Cancer Center NCTN Lead Academic Participating Site

案例综合癌症中心 NCTN 领先学术参与站点

• 批准号: 9894765
• 负责人: Aaron Thomas Gerds
• 金额: $ 148.45万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9894765
• 关键词: Address; Advisory Committees; American College of Radiology Imaging Network; Biological Markers; Brain; Breast; Cancer Center; Cancer Patient; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Communication; Communities; Community Clinical Oncology Program; Component of the National Cancer Institute; Comprehensive Cancer Center; County; Data; Data Analyses; Development; Developmental Therapeutics Program; Diagnosis; Diagnostic; Disease; Eastern Cooperative Oncology Group; Education; Educational process of instructing; Ensure; Faculty; Funding; Future; Generations; Genitourinary system; Goals; Gynecologic; Hematology; Hospitals; Image; Individual; Industry; Infrastructure; Institution; Investigation; Lead; Leadership; Lung; Malignant Neoplasms; Medical; Mentors; Meta-Analysis; Minority; Mission; Multi-Institutional Clinical Trial; National Cancer Institute; National Clinical Trials Network; Ohio; Oncology; Operative Surgical Procedures; Orphan; Patient Care; Patients; Phase; Physicians; Pilot Projects; Population Heterogeneity; Positioning Attribute; Procedures; Protocols documentation; Quality Control; Quality of life; Radiation; Research; Research Personnel; Role; Services; Site; Southwest Oncology Group; System; Time; Tissue Sample; Translational Research; Underrepresented Populations; Universities; University Hospitals; Vision; base; biobank; cancer care; cancer therapy; cancer type; clinical infrastructure; data management; data submission; design; experience; gastrointestinal; improved; improved outcome; industry partner; innovation; interest; medical schools; medical specialties; meetings; melanoma; member; operation; performance site; phase II trial; programs; prospective; protocol development; quality assurance; rare cancer; recruit; secondary analysis; success

PROJECT SUMMARY This project represents the comprehensive efforts of the oncology community at Case Western Reserve University School of Medicine and its three major teaching affiliate hospitals (University Hospitals, Cleveland Clinic, and MetroHealth) to participate as a Lead Academic Participating Site in the National Clinical Trials Network (NCTN). The NCTN, funded and directed by the National Cancer Institute (NCI), is the major consortium for performing federally-funded, national multicenter clinical trials that aim to improve outcomes for cancer patients. The emphasis of NCTN trials is late phase (phase III and relatively large Phase II) trials that address scientific questions that usually cannot be answered by other means such as a single-institution study or an industry company study. The results of these trials often set the standards of care for cancer treatment in the U.S. and the world. This includes clinical trials research in rare cancers and underrepresented populations. Our specific aims for this project are 1) to participate in NCTN trials with exceptionally high levels of accrual volume and quality of data generation and submission for approximately 240 new patients per year; 2) to serve the NCTN and the cancer community by providing scientific and administrative leadership in the (Cooperative) Groups that design and operate these NCTN clinical trials in the entire broad portfolio of cancers; in particular we are full members with many investigator leaders within NRG Oncology, ECOG-ACRIN and SWOG; and 3) to perform and present hypothesis-based, investigator-led research that benefits future NCTN research. This includes secondary clinical and biorepository translational analyses from NCTN data and pilot studies from our institution. We achieve these aims by assembling an outstanding core of investigators representing all the major cancer specialties (surgical, radiation, medical and diagnostic oncology) and disease sites (hematologic, lung, breast, gastrointestinal, genitourinary, brain, gynecologic and melanoma). We have also developed a robust infrastructure of clinical trials operations in support of the NCTN, including the centralized facilities at Case Western and the hospital-based clinical trials units. They ensure timely activation of, and education about, NCTN trials, accrual enhancement, regulatory management and a high quality of research procedures and data submission. Finally, a major priority is the recruitment, development and mentoring of new Case Western investigators' involvement within the NCTN, including their participation in the Groups' activities such as their semi-annual meetings and committee assignments.

项目总结